HDAC9 and leukemia: Aberrant activation or overexpression of HDACs has been reported in various cancers including leukemia [32, 33], and HDAC inhibitors represent a new class of targeting agents that have been developed and still in different stages of clinical trials for the treatment of both hematologic and solid malignancies [34, 35].